CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Negative Risk Markers for Cardiovascular Events in the Elderly A Combined Optical Coherence Tomography and Intravascular Ultrasound Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in Patients With ST-Segment Elevation Myocardial Infarction: Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes : Insights From PROSPECT Prognostic value of coronary artery calcium screening in subjects with and without diabetes Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: serial intravascular ultrasound analysis from the sirius trial

Review Article2018 Jun 13.[Epub ahead of print]

JOURNAL:Eur Heart J. Article Link

Heart failure with preserved ejection fraction: from mechanisms to therapies

Lam CSP, Voors AA, de Boer RA et al. Keywords: HFpEF; mechanisms; therapy

ABSTRACT


This review aims to provide a translational perspective on recent developments in heart failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential therapies. A key concept in this review is that HFpEF is a haemodynamic condition wherein the heart fails to keep up with the circulatory demands of the body, or does so at the expense of raised left ventricular filling pressures. We, therefore, propose that the 'final common pathway' for development of congestion, i.e. basic haemodynamic mechanisms of increased left ventricular end-diastolic pressure, left atrial hypertension, pulmonary venous congestion, and plasma volume expansion, represents important initial targets for therapy in HFpEF. Accordingly, we group this review into six mechanisms translating into potential therapies for HFpEF: beginning with three haemodynamic mechanisms (left atrial hypertension, pulmonary hypertension, and plasma volume expansion), and working backward to three potential molecular mechanisms [systemic microvascular inflammation, cardiometabolic functional abnormalities, and cellular (titin)/extracellular (fibrosis) structural abnormalities].